Please login to the form below

Not currently logged in
Email:
Password:

Basilea appoints commercial head

David Veitch spent 15 years at BMS

Switzerland-based biopharma Basilea has appointed David Veitch as chief commercial officer, effective September 1, 2014.

Veitch will lead the company's commercial operations, including sales, marketing and pricing.

He joins from Savient Pharmacueticals where he served as president of the company's' European operations. It's at Bristol-Myers Squibb (BMS) where Veitch has spent most of his career, however, serving at the company from 1996 to 2011 when he joined Savient.

Veitch's most senior role at BMS was senior VP for EMEA marketing and brand commercialisation.

Ronald Scott, CEO of Basilea, commented that Veitch's “extensive experience and in-depth knowledge of European pharmaceutical markets will be instrumental” as the company prepares to launch its antibiotic Zevtera in Europe in 2015.

19th August 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...